Severe asthma drug may boost daily steps, study hopes

NCT ID NCT05404763

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether mepolizumab, a drug already used to reduce asthma attacks, can also improve physical activity and exercise tolerance in people with severe asthma. Researchers will track daily steps and activity levels in 62 adults over six months. The goal is to see if better lung function from the drug leads to a more active life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

mepolizumab

What this could lead to

If successful, this could show that mepolizumab helps severe asthma patients become more physically active, potentially improving their overall health.

What could go wrong

This is a small, early-stage study with only 62 participants, so results may not apply to everyone. It focuses on activity levels, not on curing asthma.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic asthma asthma Dyspnea Motor Activity pulmonary eosinophilia T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Lille University Hospital

    Lille, France